Latest Security News

Boss Energy reported a sharp turnaround with a $34.2 million net loss for FY2025 despite generating $75.6 million in revenue, while withholding dividends amid ongoing challenges.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Volt Group Limited reports a 38% surge in EcoQuip revenue alongside steady progress in zero-emission technologies, positioning itself strongly in the clean energy transition.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Vection Technologies reports its first positive underlying EBITDA alongside a 22% pro-forma revenue increase, driven by major defence contracts and AI integration. The company’s strategic acquisition and sector diversification set the stage for sustainable growth in FY26.

Visionflex Group Limited’s FY25 results highlight a strong transition to a SaaS-driven model, with recurring revenue surging 49% to $1.9 million and total revenue up 33%. Key government and private sector contracts underpin future growth prospects.

Visionflex Group reported a 49% rise in annual recurring revenue to $1.9 million despite a 33% drop in total revenue, driven by a pivot to subscription models and key government and corporate contracts.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.